New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses

Figures & data

Figure 1. Detailed retrieval strategy. Forest map (control).

Table 1. Kappa.

Symmetrical measurement		Value	Asymptotic standard error^a	Approximate T^b	Progressive significance
Protocol measurement	Kappa	.968	.031	10.918	.000
valid cases		127

^aSince a is constant, no statistics are calculated.

^bOriginal assumptions are not assumed.

Table 2. Characteristics of the included studies (demography).

Included in the study (Author and year)	Sample		Sex (man/female)		note	Nos score	JBI score
	experience	control	experience	control
Glover 2022 [43]	35	23			Retrospective case note review	6
Iraola 2022 [44]	53		(16/37)		Retrospective cohort study		8
Palma 2021 [27]	6		(0/6)		Retrospective case series		5
Nga 2021 [31]	27	11	(9/18)	(5/6)	Retrospective cohort study	6
Portoles 2021 [45]	30	4	(16/14)	(3/1)	Retrospective cohort study	6
Duineveld 2021 [46]	7		(1/6)		Retrospective study		6
Ardissino 2021 [39]	18	3	(5/13)	(1/2)	Case series study	5
Gonzalez 2021 [47]	6		(3/3)		Case series		6
Kant 2020 [28]	10	9	(2/8)	(2/7)	Retrospective analysis	6
Alpay 2019 [48]	8		(6/2)		Case series study		6
Duineveld 2017 [49]	1	16	(0/1)	(11/5)	Case series	4
Andrade 2017 [29]	6		(3/3)		Case series		6
Manani 2017 [50]	3	1	(1/2)	(1/0)	Case series	4
Legendre 2017 [51]	26		(10/16)		Case series		7
Levi 2017 [30]	12		(6/6)		Retrospective observational study		8
Mallett 2015 [33]	4		(0/4)		Retrospective cohort study		5
Matar 2014 [38]	7	5	(2/5)	(2/3)	Retrospective study	4
Zuber 2012 [52]	14				Retrospective multicenter study		5

Table 3. Characteristics of the included studies.

Included in the study (Author and year)	Interventions (Eculizumab)		Outcome
Glover 2022 [22]	Prevention: 900 mg, then 1200 mg		AHUS recurrence, dialysis, Serum creatinine, eGFR, rejection
Iraola 2022 [43]	/		AHUS recurrence, dialysis, Serum creatinine, eGFR, LDH, PLT
Palma 2021 [31]	/		AHUS recurrence, dialysis
Nga 2021 [34]	Treatment: 900 mg, 1200 mg	Prevention: 900 mg, and 1200 mg	AHUS recurrence, rejection, dialysis
Portoles 2021 [45]	900 mg, then 1200 mg		AHUS recurrence, dialysis, Serum creatinine
Duineveld 2021 [46]	900 mg, 1200 mg		AHUS recurrence, Serum creatinine
Ardissino 2021 [39]	customized		AHUS recurrence, dialysis, rejection, Serum creatinine
Gonzalez 2021 [47]	1200 mg then 900 mg/week 4 times, then 1200 mg		AHUS recurrence, rejection, dialysis, Serum creatinine
Kant 2020 [28]	Treatment: 900 mg, then 1200 mg	Prevention:1200  mg, 900  mg,1200  mg	AHUS recurrence, dialysis, Serum creatinine, eGFR
Alpay 2019 [48]	900 mg, 1200 mg		AHUS recurrence, rejection, Serum creatinine, LDH
Duineveld 2017 [49]	/		AHUS recurrence, rejection, Serum creatinine, eGFR
Andrade 2017 [29]	Treatment: 900 mg; 1200 mg,	Prevention: 900  mg, 1200  mg	AHUS recurrence, Serum creatinine, eGFR, LDH, PLT
Manani 2017 [50]	customized		AHUS recurrence, dialysis, rejection
Legendre 2017 [51]	900 mg, 1200 mg		AHUS recurrence, rejection, dialysis, eGFR, LDH, PLT
Levi 2017 [30]	Treatment: 900 mg, then 1200 mg	Prevention: 1200  mg, 900  mg. Then 1200  mg	AHUS recurrence, rejection, dialysis, Serum creatinine, eGFR
Mallett 2015 [33]	900mg, 1200 mg		AHUS recurrence, rejection, Serum creatinine, LDH, PLT
Matar 2014 [38]	/		AHUS recurrence, dialysis, Serum creatinine, eGFR
Zuber 2012 [52]	/		AHUS recurrence

Note. eGFR: glomerular filtration ratep; LDH: lactate dehydrogenase; PLT: platelet count.

Figure 2. Meta-analysis of single-arm studies.

Figure 3. Serum creatinine.

Figure 4. Funnel plot of serum creatinine.

Figure 5. AHUS recurrence.

Figure 6. Funnel plot of AHUS recurrence.

Figure 7. Dialysis.

Figure 8. Funnel plot of dialysis.

Figure 9. Rejection.

Figure 10. Funnel plot Rejection. Forest map (without control) appendix.

Glover EK, Smith-Jackson K, Brocklebank V, et al. Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023;107(4):994–1003. doi:10.1097/TP.0000000000004355.

 PubMed Web of Science ®Google Scholar

Gema Ariceta Iraola M, Al-Dakkak I, Anokhina K, et al. FC 115: long-term outcomes in Eculizumab-Treated kidney transplant patients enrolled in the global atypical haemolytic uraemic syndrome registry. Nephrol Dial Transpl. 2022;37(Supplement_3). doi:10.1093/ndt/gfac123.004.

 Google Scholar

Palma LMP, Eick RG, Dantas GC, et al. Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J. 2021;14(4):1126–1135. doi:10.1093/ckj/sfaa062.

 PubMed Web of Science ®Google Scholar

Baskin E, Fidan K, Gulhan B, et al. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. 2022;35(4):1213–1222. doi:10.1007/s40620-021-01212-w.

 PubMed Web of Science ®Google Scholar

Portoles J, Huerta A, Arjona E, et al. Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J. 2021;14(4):1173–1180. doi:10.1093/ckj/sfaa096. PMID: 33841863; PMCID: PMC8023214.

 PubMed Web of Science ®Google Scholar

Duineveld C, Bouwmeester R, van der Heijden JW, et al. Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clin Kidney J. 2021;14(8):1939–1945. doi:10.1093/ckj/sfaa241.

 PubMed Web of Science ®Google Scholar

Ardissino G, Cresseri D, Tel F, et al. Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored eculizumab. J Nephrol. 2021;34(6):2027–2036. doi:10.1007/s40620-021-01045-7.

 PubMed Web of Science ®Google Scholar

González CC, López-Jiménez V, Vázquez-Sánchez T, et al. Efficacy and safety of eculizumab in kidney transplant patients with primary atypical hemolytic-uremic syndrome. Transplant Proc. 2022;54(1):25–26. doi:10.1016/j.transproceed.2021.09.063.

 PubMed Web of Science ®Google Scholar

Kant S, Bhalla A, Alasfar S, et al. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience. BMC Nephrol. 2020;21(1):189. doi:10.1186/s12882-020-01847-0.

 PubMed Web of Science ®Google Scholar

Alpay N, Ozçelik U. Renal transplantation in patients with atypical hemolytic uremic syndrome: a single center experience. Transplant Proc. 2019;51(7):2295–2297. doi:10.1016/j.transproceed.2019.01.157.

 PubMed Web of Science ®Google Scholar

Duineveld C, Verhave JC, Berger SP, et al. Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis. 2017;70(6):770–777. doi:10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16. PMID: 28821363.

 PubMed Web of Science ®Google Scholar

de Andrade LGM, Contti MM, Nga HS, et al. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One. 2017;12(11):e0188155. doi:10.1371/journal.pone.0188155

 PubMed Web of Science ®Google Scholar

Milan Manani S, Virzì GM, Giuliani A, et al. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron. 2017;136(3):245–253. doi:10.1159/000468528.

 PubMed Web of Science ®Google Scholar

Legendre CM, Campistol JM, Feldkamp T, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30(12):1275–1283. doi:10.1111/tri.13022.

 PubMed Web of Science ®Google Scholar

Levi C, Frémeaux-Bacchi V, Zuber J, et al. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation. 2017;101(12):2924–2930. doi:10.1097/TP.0000000000001909.

 PubMed Web of Science ®Google Scholar

Ariceta G, Fakhouri F, Sartz L, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14(9):2075–2084. Jan 24 doi: 10.1093/ckj/sfab005. PMID: 35261761;

 PubMed Web of Science ®Google Scholar

Matar D, Naqvi F, Racusen LC, et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98(11):1205–1212. doi:10.1097/TP.0000000000000200. PMID: 24933457.

 PubMed Web of Science ®Google Scholar

Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–3354. doi:10.1111/j.1600-6143.2012.04252.x.

 PubMed Web of Science ®Google Scholar

Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses [EB/OL]. Ottawa: OHRI; 2012.

 Google Scholar

Nga HS, Palma LMP, Ernandes Neto M, et al. Thrombotic microangiopathy after kidney transplantation: analysis of the Brazilian atypical hemolytic uremic syndrome cohort. PLoS One. 2021;16(11):e0258319. pone.0258319 doi:10.1371/journal.

 PubMed Web of Science ®Google Scholar